Oppenheimer Maintains Outperform on Modular Medical, Lowers Price Target to $3.5
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Steven Lichtman maintains an Outperform rating on Modular Medical (NASDAQ:MODD) but lowers the price target from $6 to $3.5.
May 19, 2023 | 10:47 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Oppenheimer analyst Steven Lichtman maintains an Outperform rating on Modular Medical but lowers the price target from $6 to $3.5.
The news directly mentions Modular Medical (NASDAQ:MODD) and the lowered price target by Oppenheimer analyst Steven Lichtman. While the Outperform rating is maintained, the reduced price target may create mixed sentiment among investors, leading to a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100